Alcoholic Hepatitis - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 76
Inquire Before Buying

Alcoholic Hepatitis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2018, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Alcoholic Hepatitis - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alcoholic Hepatitis - Overview
Alcoholic Hepatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alcoholic Hepatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alcoholic Hepatitis - Companies Involved in Therapeutics Development
DURECT Corp
Generon (Shanghai) Corp Ltd
Gilead Sciences Inc
GRI Bio Inc
Immuron Ltd
Intercept Pharmaceuticals Inc
Promethera Biosciences SA
Verlyx Pharma Inc
Vital Therapies Inc
Alcoholic Hepatitis - Drug Profiles
AF-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Acute Liver Failure and Alcoholic Hepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRI-0621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentamidine isethionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMKM-02GI1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selonsertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-4A32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alcoholic Hepatitis - Dormant Projects
Alcoholic Hepatitis - Product Development Milestones
Featured News & Press Releases
Apr 25, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
Mar 22, 2018: Vital Therapies Announces VTL-308 Reaches Enrollment Target of 150 Subjects
Jun 05, 2017: Vital Therapies Announces Characteristics of Early Subjects in VTL-308 Pivotal Study of ELAD System in Severe Alcoholic Hepatitis
May 23, 2016: Vital Therapies Enrolls First Subject in VTL-308
Nov 23, 2015: Generon Collaborating with Mayo Clinic to Initiate a Phase IIa Study with F-652, a First-in-Class Biologic, to Treat Patients with Alcoholic Hepatitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Alcoholic Hepatitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Alcoholic Hepatitis - Pipeline by DURECT Corp, H2 2018
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2018
Alcoholic Hepatitis - Pipeline by Gilead Sciences Inc, H2 2018
Alcoholic Hepatitis - Pipeline by GRI Bio Inc, H2 2018
Alcoholic Hepatitis - Pipeline by Immuron Ltd, H2 2018
Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals Inc, H2 2018
Alcoholic Hepatitis - Pipeline by Promethera Biosciences SA, H2 2018
Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc, H2 2018
Alcoholic Hepatitis - Pipeline by Vital Therapies Inc, H2 2018
Alcoholic Hepatitis - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Alcoholic Hepatitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Laxatives Market Insights, Forecast to 2025
    Published: 23-Jan-2019        Price: US 3900 Onwards        Pages: 113
    Laxatives are substances that loosen stools and increase bowel movements. They are used to treat and/or prevent constipation. Laxatives vary as to how they work and the side effects they may have. Bulk-forming laxatives, also known as roughage, are substances, such as fiber in food and hydrophilic agents in over-the-counter drugs, that add bulk and water to stools so that they can pass more easily through the intestines (lower part of the digestive tract). Emollient laxatives, also known ......
  • Global Gastroparesis Drugs Market Size, Status and Forecast 2019-2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 99
    Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. The idiopathic gastroparesis segment dominated the global gastroparesis drugs market during 2017 and the segment is expected to continue its dominance during the next few years as well. The market is witnessing the development of new and effective therapies for the symptomatic control of idiopathic gastroparesis, which will be one of the major factors r......
  • Global Gastrointestinal OTC Drugs Market Size, Status and Forecast 2019-2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 90
    Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country. In 2018, the global Gastrointestinal OTC Drugs market size was xx million US$ and it is e......
  • Anti Peptic Ulcer Drugs Markets in China
    Published: 17-Jan-2019        Price: US 4000 Onwards        Pages: 211
    China's demand for Anti Peptic Ulcer Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity,......
  • Anti Peptic Ulcer Drugs Companies in China
    Published: 17-Jan-2019        Price: US 1800 Onwards        Pages: 54
    This study focuses on China's Anti Peptic Ulcer Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumpt......
  • Anti Peptic Ulcer Drugs Industry Forecasts - China Focus
    Published: 17-Jan-2019        Price: US 1800 Onwards        Pages: 107
    This study focuses on China's Anti Peptic Ulcer Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and servi......
  • Global Exocrine Pancreatic Insufficiency Market Size, Status and Forecast 2019-2025
    Published: 17-Jan-2019        Price: US 3900 Onwards        Pages: 95
    Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas. EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI.......
  • Helicobacter Pylori Infections - Market Insight, Epidemiology and Market Forecast - 2028
    Published: 15-Jan-2019        Price: US 6250 Onwards        Pages: 100
    DelveInsight's "Helicobacter Pylori Infections - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Helicobacter Pylori Infections epidemiology and market outlook for the 7MM. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Helicobacter Pylori Infections Understanding and Treatment Algorithm The mar......
  • Short Bowel Syndrome - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Short Bowel Syndrome - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Short Bowel Syndrome epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Short Bowel Syndrome Epidemiology The epidemiology......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs